NBIX News and Press, Neurocrine Biosciences Inc. From 02/11/22

Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q4 2021 Earnings Call Feb 11, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NBIX) Q4 2021 Results Conference Call February 11, 2022 08:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer and Director Matt Abernethy - Chief Financial Officer Dr. Eiry Roberts - Chief Medical...

Recording the biggest intraday gain since March 2021, Neurocrine Biosciences (NBIX +5.9%) is trading sharply higher on above-average volume despite its lower-than-expected financials for Q4 2021, as reported by the company on Friday before the market open. Backed by ~32% YoY growth in total p...

Neurocrine Biosciences press release (NASDAQ:NBIX): Q4 Non-GAAP EPS of $0.04 misses by $0.84. Revenue of $312M (+25.9% Y/Y) misses by $5.72M. "As we exited last year with restored growth for INGREZZA, investments we are making this year will further accelerate our ability to help many more pa...

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 INGREZZA® (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA® (valbenazine) 2022 Net Product Sales Guidan...

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q4 earnings results on Friday, February 11th, before market open. The consensus EPS Estimate is $0.88 (-3.3% Y/Y) and the consensus Revenue Estimate is $317.72M (+28.2% Y/Y). Over the last 2 years, NBIX has beaten EPS estimates 50%...

AB, APO, ARES, AXL, BRKR, CAE, CLF, COOP, D, ENB, ESNT, FTS, G, GP, GPRE, GT, IAA, MGA, NBIX, NMRK, NWL, PRLB, TYME, UA, UAA, WPC For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Friday's open

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results Conference Call and Webcast Scheduled for Friday, February 11 PR Newswire SAN DIEGO , Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc....

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions INGREZ...

Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual 40 th Annual J.P. Morgan Healthcare Confer...